AVZ Antiviral Toolkit 5.77 for mac download

UK regulatory agency cleared path for submission of CF triple combination patient study in Q4

Positive POC with GLPG1690 in IPF patients IL-17C antibody MOR106 showed promising signs of activity in atopic dermatitis patients in Phase 1b study

Studies with filgotinib started in uveitis and lupus membranous nephropathy Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, The information contained in this Report on Form 6-K, including the exhibits,Įxcept for the quote of Onno van de Stolpe and the quote of Bart Filius contained in Exhibit 99.1, is hereby incorporated by reference into the Companys Registration Statements on Forms F-3 (File No. 333-211765) and S-8 (File Nos. On October 26, 2017, the Company announced its unaudited third quarter results for 2017, which are further described in a Q3 2017 report. Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is The registrant files or will file annual reports under cover of Form 20-F or Form 40-F. (Translation of registrants name into English) UNDER THE SECURITIES EXCHANGE ACT OF 1934

AVZ Antiviral Toolkit 5.77 for mac download